Larson Financial Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-36
| Closed | -$141 | – | 1930 |
|
|
2023
Q3 | $141 | Hold |
36
| – | – | ﹤0.01% | 1648 |
|
|
2023
Q2 | $117 | Sell |
36
-1
| -3% | -$3 | ﹤0.01% | 1515 |
|
|
2023
Q1 | $134 | Hold |
37
| – | – | ﹤0.01% | 1485 |
|
|
2022
Q4 | $1.19K | Hold |
37
| – | – | ﹤0.01% | 1265 |
|
|
2022
Q3 | $2K | Hold |
37
| – | – | ﹤0.01% | 1162 |
|
|
2022
Q2 | $2K | Hold |
37
| – | – | ﹤0.01% | 1077 |
|
|
2022
Q1 | $3K | Sell |
37
-257
| -87% | -$21.4K | ﹤0.01% | 887 |
|
|
2021
Q4 | $36K | Sell |
294
-1,191
| -80% | -$201K | 0.01% | 445 |
|
|
2021
Q3 | $209K | Sell |
1,485
-83
| -5% | -$16.4K | 0.04% | 144 |
|
|
2021
Q2 | $431K | Buy |
1,568
+6
| +0.4% | +$1.51K | 0.1% | 79 |
|
|
2021
Q1 | $334K | Buy |
1,562
+144
| +10% | +$39.8K | 0.1% | 77 |
|
|
2020
Q4 | $343K | Buy |
1,418
+295
| +26% | +$36.5K | 0.12% | 71 |
|
|
2020
Q3 | $118K | Buy |
1,123
+121
| +12% | +$11K | 0.05% | 119 |
|
|
2020
Q2 | $98K | Hold |
1,002
| – | – | 0.05% | 137 |
|
|
2020
Q1 | $75K | Buy |
1,002
+639
| +176% | +$60.8K | 0.05% | 131 |
|
|
2019
Q4 | $30K | Hold |
363
| – | – | 0.02% | 190 |
|
|
2019
Q3 | $44K | Hold |
363
| – | – | 0.03% | 158 |
|
|
2019
Q2 | $65K | Hold |
363
| – | – | 0.05% | 104 |
|
|
2019
Q1 | $58K | Buy |
363
+82
| +29% | +$16.2K | 0.05% | 108 |
|
|
2018
Q4 | $73K | Buy |
+281
| New | +$56.6K | 0.07% | 90 |
|
Other funds holding EVLO
Larson Financial Group's EVLO Position: Q4 2023 in Review
Larson Financial Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 36 shares — an estimated $141 sold.
Larson Financial Group first reported a position in EVLO in Q4 2018 and held it in 20 quarters. The position peaked at $431K in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Larson Financial Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Larson Financial Group sold 36 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $141.
- Larson Financial Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2018 and held it in 20 quarters.
- Larson Financial Group's Evelo Biosciences, Inc. Common Stock position peaked at $431K in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Larson Financial Group's 13F filing for Q4 2023, filed 1 Feb 2024.